Navigation Links
Onyx Pharmaceuticals Announces First Quarter 2011 Financial Results Teleconference and Webcast
Date:4/21/2011

SAN FRANCISCO, April 21, 2011 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that it will host a webcast and teleconference with management to discuss first quarter 2011 financial results, as well as provide a general business overview on Wednesday, May 4, 2011, at 8:00 a.m. Eastern Time (5:00 a.m. Pacific Time; 2:00 p.m. Central European Time).  Financial results for the first quarter ended March 31, 2011 will be released earlier that day.

Interested parties may access a live webcast of the presentation on the company's website at: http://www.onyx-pharm.com/investors/event-calendarWithin the U.S.:

888-771-4371International:

847-585-4405Passcode:

29609004#A replay of the presentation will be available on the Onyx website or by dialing:Dial in:

630-652-3042 Passcode:

29609004# (approximately one hour after the teleconference concludes)  The replay will be available through May 18, 2011. About Onyx Pharmaceuticals, Inc.Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of people with cancer. The company, in collaboration with Bayer HealthCare Pharmaceuticals Inc., is developing and marketing Nexavar® (sorafenib) tablets, a small molecule drug that is currently approved for the treatment of liver cancer and advanced kidney cancer. Additionally, Nexavar is being investigated in several ongoing trials in a variety of tumor types. Beyond Nexavar, Onyx has established a development pipeline of anticancer compounds at various stages of clinical testing, including carfilzomib, a selective proteasome inhibitor, that is currently being evaluated in multiple clinical trials for the treatment of patients with relapsed or relapsed/refractory multiple myeloma in various settings and solid tumors. ONX 0801, an alpha-folate receptor targeted inhibitor of thymidylate synthase, and ONX 0912, an oral proteasome inhibitor, are currently in Phase 1 testing. For more information about Onyx, visit the company's website at www.onyx-pharm.com.


'/>"/>
SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Savient Pharmaceuticals to Hold First Quarter 2011 Financial Results
2. Fleming Pharmaceuticals Now Ready to Step Up Production of Nuclear Radiation Safeguard, ThyroShield®
3. Marinus Pharmaceuticals Announces Commencement of Phase 2 Trial of Ganaxolone for the Treatment of Posttraumatic Stress Disorder
4. Hanmi Pharmaceuticals to Acquire the Rights for a Promising Phase II Anti-cancer Src Kinase/Pretubulin Dual Inhibitor from Kinex Pharmaceuticals, in Selected Asian Territories
5. Merrimack Pharmaceuticals Announces that Recruitment is Open in a Phase 1 Combination Study of MM-111 with Multiple Treatment Regimens in HER2 Positive Patients
6. Valeant Pharmaceuticals Announces Redemption of 4.0% Convertible Subordinated Notes Due 2013
7. Auxilium Pharmaceuticals to Present at the Deutsche Bank 36th Annual Health Care Conference
8. Sagent Pharmaceuticals Upsizes and Prices Initial Public Offering
9. Amira Pharmaceuticals Receives Orphan Drug Status for a Novel LPA1 Antagonist, AM152, for the Treatment of Idiopathic Pulmonary Fibrosis
10. Cumberland Pharmaceuticals Announces New Product Addition With Hepatoren™ (ifetroban) Injection
11. Bexion Pharmaceuticals Receives Outstanding Biotech Innovation Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... 2016 Aesthetic Devices - Medical Devices Pipeline ... report, "Aesthetic Devices - Medical Devices Pipeline Assessment, 2015" ... stage. This report is prepared using ... by GlobalData,s team of industry experts. *Note: Certain ... based on the availability and relevance of data in ...
(Date:2/8/2016)... 2016  Ventana Medical Systems, Inc. (Ventana), a member ... world,s top oncologists, pathologists, research scientists and healthcare ... annual Tucson Symposium March 8-9 to learn ... outcomes in cancer research and treatments that will ... Thomas Grogan , annually draws more than 500 ...
(Date:2/8/2016)... LEAWOOD, Kan. , Feb. 8, 2016 ... held organization that formerly specialized in the ... facilities, recently announced that it has divided ... Nueterra Capital. While Nueterra Capital will continue ... advisory services, NueHealth will operate a national ...
Breaking Medicine Technology:
(Date:2/9/2016)... (PRWEB) , ... February 09, 2016 , ... Establishment Labs, ... of Dr. David Hung to the company´s Board of Directors. , “We ... class scientist and an exceptional entrepreneur.” said Juan Jose Chacon Quiros, CEO of Establishment ...
(Date:2/9/2016)... ... 09, 2016 , ... ZipHearing.com is proud to ... hearing aids , increase industry transparency, and promote awareness of hearing solutions ... “For the average consumer, the hearing aid industry is esoteric and difficult to ...
(Date:2/9/2016)... ... February 09, 2016 , ... Sir Grout, ... , is proud to announce that many of their franchises have received the ... The hard surface restoration franchises received customer recognition through positive reviews and testimonials, ...
(Date:2/8/2016)... , ... February 08, 2016 , ... ... its newly redesigned website, federallabs.org . The site houses a wealth of ... available federal technologies through the process called technology transfer (T2). As a network ...
(Date:2/8/2016)... ... ... man who has struggled to quit smoking, a man who has struggled with hair loss ... to his problems – and he did. Now Nabat, a serial entrepreneur featured as the ... inventions to the world and better people's lives. His own experience with nicotine addiction led ...
Breaking Medicine News(10 mins):